Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer
Authors: Stephen B. Strum
Journal: Annals of Internal Medicine (2018)

Letters20 March 2018Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate CancerStephen B. Strum, MDStephen B. Strum, MDMedical Oncologist Specializing in Prostate Cancer, Jacksonville, Oregon (S.B.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0701 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Alibhai and colleagues' (1) review on bone health in men with nonmetastatic prostate cancer sheds light on unaddressed topics related to bone integrity in this population. Smith and associates (2) published findings that assessed bone density in men with prostate cancer who were hormone-naive by using both quantitative computed tomography and dual-energy x-ray absorptiometry. The latter is considered the gold standard; however, its use is confounded by osteoarthritis, degenerative joint disease, and vascular calcifications in vessels near the lumbar spine and hip, all of which increase in the aging population that comprises most men with prostate cancer. ...References1. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, et al. Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2017;167:341-50. [PMID: 28785760]. doi:10.7326/M16-2577 LinkGoogle Scholar2. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91:2238-45. [PMID: 11413511] CrossrefMedlineGoogle Scholar3. Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 2001;491:91-3. [PMID: 11226426] CrossrefMedlineGoogle Scholar4. Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol. 2005;44:742-7. [PMID: 16227166] CrossrefMedlineGoogle Scholar5. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? [Letter]. Ann Oncol. 2006;17:1336-7. [PMID: 16524968] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Medical Oncologist Specializing in Prostate Cancer, Jacksonville, Oregon (S.B.S.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0701. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer Shabbir M.H. Alibhai , Katherine Zukotynski , Cindy Walker-Dilks , Urban Emmenegger , Antonio Finelli , Scott C. Morgan , Sebastién J. Hotte , George A. Tomlinson , and Eric Winquist Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer Shabbir M.H. Alibhai , Katherine Zukotynski , and Cindy Walker-Dilks Metrics 20 March 2018Volume 168, Issue 6Page: 459KeywordsAgingBoneBone densityCalciumComputed axial tomographyOsteoclastsParathyroid hormonePhoton absorptiometryProstate cancerTestosterone ePublished: 20 March 2018 Issue Published: 20 March 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...